June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Quality-adjusted life year analysis of engineered corneal endothelium transplant for a Hispanic Population
Author Affiliations & Notes
  • Jorge E Valdez
    Terapias Aavanzadas en Ciencias Visuales, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Marge Vaikjarv
    Civitta, Estonia
  • Cirian Oneill
    Queens University, United Kingdom
  • Sead Zejnel
    Cardiology University Clinic, Macedonia (the former Yugoslav Republic of)
  • Gabriela Tavcioska
    General Hospital "Borka Taleski, Macedonia (the former Yugoslav Republic of)
  • Judith Zavala
    Terapias Aavanzadas en Ciencias Visuales, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Footnotes
    Commercial Relationships   Jorge Valdez None; Marge Vaikjarv None; Cirian Oneill None; Sead Zejnel None; Gabriela Tavcioska None; Judith Zavala None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2355. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jorge E Valdez, Marge Vaikjarv, Cirian Oneill, Sead Zejnel, Gabriela Tavcioska, Judith Zavala; Quality-adjusted life year analysis of engineered corneal endothelium transplant for a Hispanic Population. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2355.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Corneal blindness leads to severe decrease in life quality, including higher general mortality and associated lost productivity. Transplantation of donated corneal tissue is the only current treatment, which is limited by the lack of donors. Tissue engineering has potential to produce transplantable corneal tissue. We aimed to assess the cost-effectiveness of engineered corneal endothelium in comparison with the current treatment and a quality-adjusted life year analysis (QALY) in Mexican population using a Markov model.

Methods : For the analysis we built a Markov model. We assume there are 3 health states: blind, see, or dead. They could transition between the blindness and see transition and between these states and death. Calling this last “the absorbing state”. The state blind was considered the initial state. We assumed individuals have a transplant that restores vision which may or not work. We assumed the harvested cells from a donor cornea can be used to produce 10x more corneal transplants. We took a hypothetical cohort of 1000 blind patients aged 35 years and ran the Markov model for 40 years to reach life expectancy. The discount rate for the calculations was 3.5% and considered for 10 years. We assumed that the harvesting process and final operation cost per patient would be the same. With more transplants available we assumed the intervention will decrease waiting list from 3 to 1 year. We considered a 2020 gross domestic product (GDP) per capita in Mexico of 8,346.70 USD. We compared the price for QALY per gained with the GDP per capita in Mexico. The survival rate/duration of the transplant was 87% for 1y, 72% for 3y, 54% for 6y and 42% for 10y

Results : The QALY gained was 0.074 and 0.74 for corneal endothelium transplant and engineered corneal endothelium, respectively. Considering that the scale of QALY value ranges from 0 (death) to 1 (perfect health), the engineered corneal endothelia will considerably benefit the Mexican population.

Conclusions : The intervention of engineered corneal endothelium the Mexican population will be cost-effective. These assumptions would be transferable to other Latin-American countries. Further cost-utility analysis will provide more detailed results.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×